title: Quality of life in type 2 diabetes patients under intensive multitherapy.
abstract: OBJECTIVE
  To assess the impact of an intensive multitherapy (IMT) on perceived quality of life (QOL), attitudes, knowledge and diabetes self-management in patients with poorly controlled type 2 diabetes.
  
  
  METHODS
  A 12-month randomized trial was conducted in 72 patients with type 2 diabetes, HbA1c>or=8%, blood pressure (BP)>130/80 mmHg and dyslipidemia. Subjects were assigned to the IMT or control group, each n=36. IMT consisted in monthly visits including clinical and biochemical assessment, education sessions on diet, physical exercise, medical management of diabetes and associated diseases and adjustments in medication. Control patients were under the care of their physicians. We developed and validated a diabetes-specific questionnaire assessing QOL, attitudes, knowledge, diabetes self-management and socio-demographic data for this study. Outcomes were measured at 0, 6 and 12 months.
  
  
  RESULTS
  Subjects were 54.8+/-8.1 years old (duration of diabetes: 10.3+/-7.2 years). At baseline, questionnaires showed no difference in QOL between groups. At 12 months, QOL improved significantly in the IMT group when compared to controls (+13.2+/-10.3/+5.6+/-13.2%, P=0.003), particularly with respect to the satisfaction scale (+25.3+/-13.9/+5.4+/-21.7%, P<0.001). QOL was not affected by complications or hypoglycaemic episodes. QOL scores improved in IMT subjects who began insulin therapy during the trial. Attitude scores, in the high normal range at baseline, did not change. Knowledge (+18.2+/-26.3/+8.9+/-30.4%, P=0.047) and diabetes self-management (+22.6+/-35.3/+6.8+/-20.1%, P<0.001) improved.
  
  
  CONCLUSIONS
  In poorly controlled subjects, QOL improved statistically despite the inherent constraints imposed by IMT.
authors.affiliation: Research Group on Diabetes and Metabolism, Clinical Research Center, Centre Hospitalier Universitaire de Sherbrooke, 3001, 12th North Avenue, Sherbrooke, J1H 5N4 Quebec, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Ménard
authors.forename: H
authors.initials: H
authors.lastname: Payette
authors.forename: N
authors.initials: N
authors.lastname: Dubuc
authors.forename: J P
authors.initials: JP
authors.lastname: Baillargeon
authors.forename: P
authors.initials: P
authors.lastname: Maheux
authors.forename: J L
authors.initials: JL
authors.lastname: Ardilouze
mesh_terms: D000328:Adult; D000368:Aged; D001007:Anxiety; D001294:Attitude to Health; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology* / Q000523:psychology*; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000150:complications; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006973:Hypertension / Q000150:complications; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011788:Quality of Life; D011795:Surveys and Questionnaires
chemical_list: D008078:Cholesterol, LDL; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents